Sleep driving: Sleepwalking variant or misuse of z-drugs?

被引:26
|
作者
Pressman, Mark R. [1 ,2 ,3 ]
机构
[1] Lankenau Inst Med Res, Lankenau Med Ctr, Sleep Med Serv, Wynnewood, PA 19096 USA
[2] Villanova Univ, Sch Law, Villanova, PA 19085 USA
[3] Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA
关键词
Sleep driving; Impaired driving; Sleepwalking; Zolpidem; Zopliclone; Zaleplon; Eszopiclone; ZOLPIDEM; SOMNAMBULISM; DRIVERS; SAFETY; PARASOMNIAS; DISORDERS; HYPNOTICS; ZOPICLONE; ZALEPLON; BLOOD;
D O I
10.1016/j.smrv.2010.12.004
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Sleep driving is most often classified as a variant of sleepwalking, but should be distinguished from impaired driving due to misuse or abuse of sedative/hypnotic drugs. Z-drugs; zolpidem and zopiclone in particular, have been associated with the majority of reported cases of impaired driving. Numerous studies have found z-drugs in driving under influence (DUI) related police stops, arrests and accidents. Impaired drivers are reported to have 1) blood levels of z-drugs that exceed therapeutic ranges 2) failed to take the medication at the correct time or remain in bed for sufficient time and/or 3) combined z-drugs with other central nervous system (CNS) depressants and/or alcohol. Consistent with CNS depression, z-drug-impaired drivers may demonstrate cognitive function at low levels with drivers still able to understand and respond to questions while sleepwalkers are completely unable to understand or interact with police. Z-drug-impaired drivers are often severely physically impaired, unable to stand up or maintain balance while sleepwalkers are able to stand and walk unaided. Sleep driving and impaired driving due to z-drugs may overlap. Sleep driving and drug-impaired driving are statistically rare events, but due to the billions of doses prescribed each year may still result in numerous DUI related arrests and accidents. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:285 / 292
页数:8
相关论文
共 50 条
  • [1] Misuse of benzodiazepines and Z-drugs in the UK
    Kapil, V.
    Green, J. L.
    Le Lait, C.
    Wood, D. M.
    Dargan, P. I.
    BRITISH JOURNAL OF PSYCHIATRY, 2014, 205 (05) : 407 - 408
  • [2] BDZs, Designer BDZs and Z-drugs: Pharmacology and Misuse Insights
    Zaami, Simona
    Graziano, Silvia
    Tittarelli, Roberta
    Beck, Renata
    Marinelli, Enrico
    CURRENT PHARMACEUTICAL DESIGN, 2022, 28 (15) : 1221 - 1229
  • [3] Z-drugs
    McCabe, Stephen
    BRITISH JOURNAL OF GENERAL PRACTICE, 2007, 57 (536): : 246 - 246
  • [5] The use of a national identification system to prevent misuse of benzodiazepines and Z-drugs in Japan
    Kinoshita, Shotaro
    Kishimoto, Taishiro
    LANCET PSYCHIATRY, 2023, 10 (10): : E26 - E26
  • [6] Z-drugs and driving: concentrations in suspected impaired driving investigations, 2021-2023
    Marco, Stephanie
    Chan-Hosokowa, Ayako
    CLINICAL TOXICOLOGY, 2024, 62 : 90 - 91
  • [7] Use and misuse of benzodiazepines and z-drugs in the French psychiatric population, an in-patients cohort
    Panes, A.
    Pariente, A.
    Fourrier-Reglat, A.
    Berdrai, D.
    Tournier, M.
    EUROPEAN PSYCHIATRY, 2018, 48 : S449 - S449
  • [9] Prevalence and correlates of the misuse of z-drugs and benzodiazepines in the National Survey on Drug Use and Health
    McHugh, R. Kathryn
    Votaw, Victoria R.
    Trapani, Emma W.
    McCarthy, Megan D.
    FRONTIERS IN PSYCHIATRY, 2023, 14
  • [10] Presentations to the Emergency Department with misuse of benzodiazepines and Z-drugs: profiling and relation to sales data
    Lyphout, Cathelijne
    Yates, Christopher
    Dugan, Paul I.
    Margolin, Zachary R.
    Dines, Alison
    Heyerdahl, Fridtjof
    Hovda, Knut Erik
    Giraudon, Isabelle
    Bartelson, Becki
    Green, Jody L.
    Wood, David M.
    CLINICAL TOXICOLOGY, 2018, 56 (06) : 471 - 472